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Abstract
Tuberculosis (TB) has been a leading cause of death for more than a century. While effective
therapies exist, treatment is long and cumbersome. Tuberculosis control is complicated by the
overlapping problems created by global inadequacy of public health infrastructures, the interaction of
the TB and human immunodeficiency virus epidemics, and the emergence of drug-resistant TB. After
a long period of neglect, there is now significant progress in development of TB diagnostics and
therapeutics. Focusing on treatment for active TB, we review the new pathways to TB regimen
development, and the new and repurposed anti-TB agents in clinical development.
Introduction
In 2010, the World Health Organization (WHO) reported
8.8 million incident cases of TB, 1.1 million deaths from
TB among HIV-negative people and an additional
0.35 million deaths from HIV-associated TB [1]. TB is
the fourth leading infectious killer of adults worldwide,
the third largest killer of women in their reproductive
years, and the leading infectious cause of death among
peoplewithHIV/AIDS [2-4].Inrecent years, the world has
seen a rapidly emerging epidemic of drug-resistant TB,
multidrug-resistant TB, and extensively drug-resistant TB,
which is highly lethal and extremely expensive and
complicated to treat [5].
Despite these sobering facts, the current first-line four-
drug regimen for drug-susceptible TB is nearly 50 years
old, takes six to nine months to complete and has
significant side effects. Treatment for drug-resistant TB
may take up to 30 months [6]. Even though more than
250,000 children develop TB each year, inexcusably,
most anti-TB agents are not available in suitable pediatric
formulations [7]. While liquid formulations may be easy
to administer to young children, they are bulky, more
expensive, and some have unacceptable toxicity, for
example isoniazid syrup, which is in a sorbitol-based
solution and causes diarrhea. Only recently have TB
drug-dosing recommendations been revised to reflect
differences in the way children metabolize drugs and,
until recently, most first-line drugs were grossly under-
dosed [8]. Equally importantly, the last time a new drug
for TB treatment was licensed was 1998 (rifapentine)
(Figure 1). There is urgent need for more effective and
tolerable treatment of drug-susceptible and drug-
resistant disease, latent TB infection, and dosing strategies
for children. Regimens that can be safely co-administered
withantiretroviral therapy are also neededfor the growing
number of patients co-infected with both HIV and TB.
Finally, after a long drought, new drugs are available and
new strategies for treatment of latent disease and for
regimen development in active disease are emerging.
There is renewed interest in the rifamycin class of drugs.
Shorter courses of treatment for latent TB look promis-
ing; in addition, studies in the mouse model suggest that
higher doses of rifampin or rifapentine may markedly
improve the treatment of drug-susceptible disease [9,10].
Fluoroquinolones may allow shorter treatment dura-
tions for drug-susceptible disease, though initial phase
IIB trials have shown inconsistent results [11]. Discussed
in more detail below, there are six novel drugs in four
new classes in clinical trials, including TMC207, OPC-
67683, PA824, SQ109, PNU-100480 and AZD5847.
These agents are anticipated to dramatically shorten and
otherwise improve the treatment of drug-resistant, and
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separately or in novel combinations.
Just as important as the new drugs are the emerging new
strategies for TB treatment regimen development, and
regulatory changes to expedite this. Since the 1950s, TB
clinical trials have consistedof addition to, or substitution
from, an existing drug in a standard regimen. Traditional
trial designs use cure without relapse as an endpoint,
which requires at least 6 months of treatment and then
12-18monthsoffollow-up.Therefore,largePhaseIIItrials
often take five or six years to complete, and with multiple
compounds now in the pipeline, development of a novel
regimen using this model would literally take decades.
Thankfully, however, the recent increase in global
philanthropy directed at TB and the unprecedented
collaboration amongst major stakeholders have created
opportunities to overcome bottlenecks and dramatically
shorten the time to regimen development. An excellent
example of such a collaborative initiative is the Critical
Path to TB Drug Regimens (CPTR) [12]. Including
researchers, drug developers, regulatory agencies and
donors,thegoalofthisprogramistoaddressthescientific,
clinical, regulatory and legal challenges posed by devel-
opment of novel drug combinations. The first clinical trial
of multiple novel agents in an early bactericidal activity
study was recently presented ([13], discussed further
below) and several more are in development. Treatment
shortening is also an important goal for the near future, as
is the development of more tolerable regimens. Suitable
formulations and regimens for children are urgently
needed. So-called “universal regimens” with activity
against drug-sensitive and multi-drug resistant/extensively
drug-resistant TB are under discussion. Future goals in TB
drug development also include identification of relevant
biomarkers to act as surrogate endpoints, rather than
waiting for relapse-free survival [14].
New applications of existing drugs
Rifamycins
Rifampicin is a cornerstone of TB treatment, largely due
to its sterilizing ability (i.e. the ability to kill dormant,
less active, as well as rapidly dividing, mycobacteria).
Surprisingly, the daily dose of 600mg currently used is
likely not on the optimal part of the dose-response curve,
and higher doses may be needed to achieve treatment-
shortening goals for drug-sensitive TB [15]. Sterilizing
activity increases with escalating doses in the mouse
model, which is often used in TB drug development and
has proved an excellent predictor of clinical trial results
in humans [9]. One possible problem with this is that
older studies suggested poor tolerability with weekly
Figure 1. Timeline for TB drug development
Major milestones in TB treatment over the last century are outlined by the date of approval of the drug or intervention. Approval dates for drugs in
development are estimated.
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sitivity reactions with “flu-like” symptoms, thrombocy-
topenia, hemolytic anemia, and renal failure [16].
However, this may not be the case with daily dosing,
and high-dose rifampicin is under study, for example in
the Rifaquin study which will evaluate high dose rifampin
and gatifloxacin (http://rifaquin.wordpress.com/); the
HIGHRIF project which is a series of 4 trials of high
dose rifampicin (http://www.edctp.org); and an NIH-
supported study in Brazil and Peru (http://clinicaltrials.
gov/ct2/show/NCT01408914).
For HIV-infected patients requiring protease inhibitor-
based therapy, rifabutin is generally recommended where
available because of reduced potential for significant
drug-drug interactions. A recent review of the scientific
literature found that rifabutin is effective and safe in this
setting [17].
From the same class, but with a longer half-life,
rifapentine is being evaluated for both latent and active
TB. In an 8,000 patient, international study of latent
infection from the TB Trials Consortium (TBTC) funded
bythe Centers for DiseaseControland Prevention(CDC),
weekly rifapentine at 900mg with isoniazid 900mg
weekly for 3 months was not inferior to the standard
9 month isoniazid regimen recommended for latent TB
infection treatment in the US [18]. The CDC guidelines
were revisedin 2011 toincludethis regimen[19]. Aneven
shorter regimen of rifapentine and isoniazid for one
month in HIV co-infected patients is under study by the
AIDS Clinical Trials Group, and Phase III trials with
rifapentine for pulmonary TB are ongoing. Somewhat
surprisingly, the Tuberculosis Trials Consortium Study 29
found similar rates of sputum culture conversion (i.e.
from positive to negative for TB) at eight weeks in 381
smear-positive patients with TB using rifampin or
rifapentine [20].
Unfortunately, all rifamycins induce phase II and P450
metabolizing enzymes, resulting in significant drug-
drug interactions when used with antiretroviral agents.
This presents a major obstacle in treatment of HIV/TB
co-infected patients with rifamycins, particularly those
who require protease inhibitor therapy [21]. Rifapen-
tine was previously considered a less potent inducer
of the metabolizing CYP3A isozyme than rifampin,
and therefore less likely to cause significant drug-drug
interactions when used with antiretroviral agents.
However, recent data in healthy volunteers at clinically
relevant doses using midazolam as a probe found
rifapentine to be a more potent inducer of CYP3A than
rifampin [22].
Fluoroquinolones
Although not licensed for TB treatment, the broad
spectrum antibiotics fluroquinolones are often used in
the treatment of drug-resistant TB and are also under
study as first-line agents. Levofloxacin, moxifloxacin,
and gatifloxacin are all active in vitro and in a mouse
model, resulting in the ability to shorten treatment to
4 months [23]. Phase II trial results with fluroquino-
lones have been inconsistent, but larger ongoing studies
will better define the contribution of this class of drugs.
A Phase II study of three fluroquinolones in 217 patients
with pulmonary tuberculosis demonstrated that gatiflox-
acin and moxifloxacin (but not ofloxacin) improved the




addition of moxifloxacin did not affect two-month
sputum culture status but did show increased activity at
earlier time points [26]. Substitution of moxifloxacin for
isoniazid resulted in a small but statistically insignificant
increase in Week 8 sputum culture negativity in TBTC
Study 28 [27]. In addition, a recent observational study
evaluated the effectiveness of standardized regimens for
patients with proven multidrug-resistant tuberculosis
previously untreated with second-line drugs in low-
income countries. The authors found that a regimen of a
minimum of nine months of treatment with gatifloxacin,
clofazimine, ethambutol, and pyrazinamide supplemen-
ted by prothionamide, kanamycin, and high-dose iso-
niazid during an intensive phase of a minimum of four
months resulted in treatment outcomes comparable to
those obtained with first-line treatment [28].
Fluoroquinolones do not have significant drug-drug
interactions with antiretroviral drugs, although adverse
effects limit utility in children and pregnant women.
Moxifloxacin may also have overlapping toxicity with
regard to prolongation of the QT interval. Several studies
of fluoroquinolones are ongoing. The Global Alliance
for TB Drug Development (http://www.tballiance.org) is
conducting a large, multicountry phase III trial using
moxifloxacin in a four-month regimen. Availability of
gatifloxacin is limited atpresent but levofloxacin is under
study in multi-drug resistant TB.
New drugs
TMC207
TMC207 (bedaquiline) is a diarylquinoline with a novel
mechanism of action by inhibiting mycobacterial ATP
synthase [29]. It has potent activity against Mycobacterium
tuberculosis isolates regardless of resistance, but little
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alone in the mouse model, TMC207 was more active
than conventional multidrug therapy combined, and
produced complete sterilization at 2 months in combi-
nation therapy [29]. In a pivotal phase II trial in patients
with multi-drug resistant TB, the drug was highly
effective and reduced response time by more than half
when given together with an optimized background
regimen, comparedtothe optimized backgroundregimen
alone [30]. Sputum culture conversion at six months was
79% in the TMC207 arm and 58% in the optimized
background regimen arm [31]. Phase III trials are in
development for this exciting new addition to the TB
armamentarium and provisional FDA approval is antici-
pated in 2013.
Bedaquiline is being developed in an unusual partner-
ship between the developer, Tibotec, and the Global
Alliance for TB Drug Development, which is a non-profit
organization. Under the terms of the agreement, Tibotec
will be responsible for the worldwide development of
and access to TMC207 for treatment of multidrug-
resistantTB. Tibotec granted the TB Alliance a royalty-
free license for the worldwide development of, and
access to, TMC207 for drug-susceptible TB.
Although the drug is a substrate of the metabolizing
enzyme CYP3A, problematic drug-drug interactions with
antiretroviral agents are not anticipated because TMC207
is only metabolized by CYP3A, but does not induce or
inhibit the enzyme. However, the drug has a very long
half-life, and unanswered questions remain about long-
term safety and tolerability. Concentrations of TMC207
resistant TB. Tibotec granted the TB Alliance a royalty-
with rifamycins, but no significant effect was seen when
given with efavirenz [32].
Despite these unknowns, TMC207 represents a major
milestone in TB drug development as it will dramatically
improve treatment of drug-resistant TB, and might also
be useful for treatment shortening in patients with
susceptible disease and for treatment of multidrug-
resistant/extensively drug-resistant TB contacts, another
urgent need in TB therapeutics.
Nitroimidazoles: PA-824 and OPC-67683 (delamanid)
The next generation of nitroimidazoles shows promise
for TB treatment. It includes PA824, under development
by the Global Alliance for TB Drug Development
following in-licensing from Chiron. The Otsuka Phar-
maceutical Company is developing a related compound,
OPC-67683 (delamanid). Both are nitrofuranylamides
with potent activity against drug-sensitive and drug-
resistant TB [33]. In mice, either drug in combination
withrifampicinandpyrazinamideshortenedTBtreatment
by at least 2 months [34,35].
A recently presented study from South Africa evaluated
TMC207, PA824 and pyrazinamide in an early bacter-
icidal activity study, which measures decline in sputum
colony counts per day among patients with sputum
smear-positive pulmonary TB [13]. Addition of pyrazina-
mide to either drug significantly increased the early
bactericidal activity, validating the mouse data described
above. A combination of PA-824 together with moxiflox-
acin and pyrazinamide in an early bactericidal activity
study found that this three-drug combination was more
effective than standard TB treatment (isoniazid, rifampin,
pyrazinamide, ethambutol), a first-ever finding in a two-
week early bactericidal activity study [36]. These ground-
breaking studies were greeted with great interest and
excitement. More novel drug combination studies are in
development, and the goal of a three-month treatment
regimen appears more achievable. The next wave of
planned trials may also use the new paradigm of a
universal regimen, and enroll patients with either drug-
susceptible or -resistant TB in the same study.
Otsuka have completed a phase II, randomized, double-
blind trial of OPC-67683 in multidrug-resistant TB
patients receiving either 100mg or 200mg twice daily
in addition to standardized second-line drugs. Results
are not available at the time of this publication, but the
dose going forward is 200mg and a phase III trial of
patients with multidrug-resistant TB is recruiting in
Eastern Europe.
A pharmacokinetic interaction study with PA824 and
commonly used antiretroviral drugs is in development,
and similar studies can proceed with OPC-6Z683 now
that a dose has been selected.
SQ109 (Sequella)
SQ109 is an analogue of ethambutol, but ten times more
active in preclinical studies [37]. In development from
Sequella, in partnership with the National Institutes of
Health, the drug is synergistic with isoniazid, rifampicin,
and TMC207 and has activity against ethambutol-
resistantstrainsinvitro[38].SQ109has adual mechanism
of action: it blocks cell wall synthesis and prevents the
efflux of companion drugs from macrophages. Multiple-
dose healthy volunteer studies are completed and clinical
trials are underway, including an extended early bacter-
icidal activity study funded by the EDCTP.
Oxazolidinones
Oxazolidinones are protein synthesis inhibitors with a
unique mechanism of action against TB [39]. This class
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linezolid is effective at doses of 1-2mg/mL against 90%
of clinical isolates [40] and works well in a mouse
model [39].
Unfortunately, long term administration of linezolid
is associated with toxicities such as neuropathy and
myelosuppression, but the drug has been evaluated
retrospectively for treatment of drug-resistant TB with
encouraging results [41,42]. Ongoing clinical trials are
investigating linezolid in patients with multidrug-
resistant and extensively drug-resistant TB.
A related oxazolidinone in development from Pfizer,
PNU100480 (Sutezolid), is superior in preclinical
models and phase I bactericidal activity studies [43].
Unlike linezolid, PNU100480 appears to have sterilizing
activity: a key factor in successful TB treatment. Addition
of the drug to a standard regimen produced a 2-log drop
in bacillary burden in the mouse model [44]. A planned
early bactericidal activity trial will help to better define
the potential role of this drug.
A little further behind in development, AstraZeneca are
developing an oxazolidinone, AZD5847. Healthy volun-
teertolerabilityandpharmacokineticstudieswererecently
completedbutresultsarenotyetavailable.AphaseIIearly
bactericidal activity study is in development.
Conclusions
This is a time of unprecedented opportunity in the field
of TB treatment. After a long drought, the pipeline for
n e wT Bt h e r a p e u t i c si sf l o w i n g .K e yo r g a n i z a t i o n s ,
companies and investigators are collaborating to develop
new treatment paradigms for treatment of latent, drug-
susceptible and drug-resistant TB in adults and in
children. Novel combinations are being tested together
rather than each drug sequentially, with the goal of
dramatically shortening the time and expense associated
with development of new regimens. Caution still needs
to be exercised with regard to identification of resistance
to the novel drugs, ensuring the optimized background
regimen offers the maximum protection possible, and
there remains a bottleneck between preclinical and
clinical development. However, there is a global
commitment to major improvements and major pro-
gress over the next decade towards a goal of eliminating
TB as a global public health crisis looks likely.
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